{"url_path":"/sec/dmac/8-k/2026-05-21/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **         **Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1401040/0001437749-26-018106-index.html","accession_number":"0001437749-26-018106","cik":"0001401040","ticker":"DMAC","issuer_name":"DiaMedica Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1401040/0001437749-26-018106-index.html","primary_entity_key":"0001401040","primary_entity_name":"DiaMedica Therapeutics Inc."},"word_count":410,"has_tables":true,"body_markdown":"**Item 5.07**         **Submission of Matters to a Vote of Security Holders.**\n\n \n\nDiaMedica Therapeutics Inc. (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “2026 AGM”) on May 20, 2026.\n\n \n\nAt the 2026 AGM, the Company’s shareholders considered four voting proposals, each of which is described in detail in the Company’s definitive proxy statement for the 2026 AGM filed with the United States Securities and Exchange Commission on April 1, 2026.\n\n \n\nThe final voting results of each voting proposal brought before a vote of the Company’s shareholders at the 2026 AGM are set forth below:\n\n \n\n**Voting Proposal One - Election of Directors**\n\n \n\nThe seven director nominees, all incumbent directors, proposed by the Board were re-elected to serve as members of the Board until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified based on the following voting results:\n\n \n\n \n \n\n**Votes For**\n\n \n \n\n**Votes Withheld**\n\n \n \n\n**Broker Non-Votes**\n\n \n\nMichael Giuffre, M.D.\n\n \n \n10,119,610\n \n \n \n229,027\n \n \n \n11,180,693\n \n\nRick Kuntz, M.D., M.Sc.\n\n \n \n10,166,733\n \n \n \n181,904\n \n \n \n11,180,693\n \n\nTanya Lewis\n\n \n \n10,136,190\n \n \n \n212,447\n \n \n \n11,180,693\n \n\nDaniel O’Connor\n\n \n \n5,217,758\n \n \n \n5,130,879\n \n \n \n11,180,693\n \n\nJames Parsons\n\n \n \n10,035,604\n \n \n \n313,033\n \n \n \n11,180,693\n \n\nRick Pauls\n\n \n \n10,178,755\n \n \n \n169,882\n \n \n \n11,180,693\n \n\nCharles Semba, M.D.\n\n \n \n10,161,380\n \n \n \n187,257\n \n \n \n11,180,693\n \n\n \n\n**Voting Proposal Two**–**Ratification of Independent Registered Public Accounting Firm**\n\n \n\nThe voting proposal to appoint Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 and authorize the Board to fix the Company’s independent registered public accounting firm’s remuneration was approved based on the following voting results:\n\n \n\n**Votes For**\n\n \n \n\n**Votes Withheld**\n\n \n \n\n**Broker Non-Votes**\n\n \n\n20,950,404\n \n \n578,926\n \n \n0\n \n\n \n\n**Voting Proposal Three**–**Advisory Vote to Approve of Executive Compensation**\n\n \n\nThe voting proposal to approve, on an advisory (non-binding) basis, the Company’s executive compensation was approved based on the following voting results:\n\n \n\n**Votes For**\n\n \n \n\n**Votes Against**\n\n \n \n\n**Abstain**\n\n \n \n\n**Broker Non-Votes**\n\n \n\n9,928,381\n \n \n271,093\n \n \n149,163\n \n \n11,180,693\n \n\n \n\n**Voting Proposal Four**–**Amendment and Restatement of the Amended and Restated 2019 Omnibus Incentive Plan**\n\n \n\nThe voting proposal to approve an amendment to the Company’s Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,500,000 shares was approved based on the following voting results:\n\n \n\n**Votes For**\n\n \n \n\n**Votes Against**\n\n \n \n\n**Abstain**\n\n \n \n\n**Broker Non-Votes**\n\n \n\n9,693,413\n \n \n510,487\n \n \n144,737\n \n \n11,180,693\n \n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n**DIAMEDICA THERAPEUTICS INC.**\n\n \n \n \n\nBy:\n\n/s/ Scott Kellen\n\nScott Kellen\n\nChief Financial Officer and Secretary\n\n \n\nDate:  May 21, 2026"}